secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ernexa Therapeutics Inc. (ERNA)
CIK:        0000748592
Form:       8-K
Filed at:   2023-07-11T23:59:59+00:00
Accession:  0001140361-23-034072
Event type: leadership
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Eterna Therapeutics appoints Binder and Wagner to Board; Singer and Cherington resign
--------------------------------------------------------------------------------

- Nicholas Singer and Charles Cherington resigned from Board on July 6, 2023; resignations not due to any disagreement.
- Board appointed Brant C. Binder (President, Bonito Biosciences) and Dr. Richard W. Wagner (CEO, Bonito Biosciences) to fill vacancies.
- Both new directors are independent under SEC/Nasdaq rules; Binder qualifies as audit committee financial expert.
- Binder and Wagner assigned to Audit, Compensation, and Nominating and Corporate Governance Committees.
- New directors will participate in standard non-employee director compensation arrangements.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/748592/000114036123034072/0001140361-23-034072-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/748592/000114036123034072/brhc20055728_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-034072

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer